NGR-hTNF regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for MolMed's NGR-hTNF to treat hepatocellular carcinoma (HCC). The recombinant fusion p...